Clinical Laserthermia Systems (CLS) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was SEK 1.3 million, down 72% year-over-year due to temporary alignment discussions with the neurosurgery partner.

• Operating loss for Q1 2026 was SEK 9.6 million, reflecting lower revenue but stable operating expenses.

• Strategic agreement post-quarter secured SEK 23 million in purchase orders for the Prism neurosurgery business, supporting future growth.

• Clinical and commercial momentum continued in the U.S. with ClearPoint PrismⓇ System installations and increased LITT procedures.

• The company is transitioning from alignment to accelerated growth, with a long-term partnership framework through 2030.

Financial highlights

• Net sales for Q1 2026: SEK 1,276 thousand, down from SEK 4,496 thousand in Q1 2025.

• Operating loss for Q1 2026: SEK 9,571 thousand, compared to SEK 7,868 thousand in Q1 2025.

• Net loss for Q1 2026: SEK 7,365 thousand, improved from SEK 15,225 thousand in Q1 2025.

• Earnings per share for Q1 2026: SEK -0.2, compared to SEK -0.7 in Q1 2025.

• Cash and cash equivalents at March 31, 2026: SEK 13,035 thousand.

Outlook and guidance

• Full-year 2026 revenue expected to show strong double-digit growth over 2025, weighted to the second half.

• Revenue visibility improved with SEK 23 million in purchase orders secured for the Prism business.

• Additional revenue anticipated from increased LITT procedures and commercial activity.

• Positive cash flow guidance updated to Q1 2028, reflecting increased near-term investments.